CNO Financial Group Third Quarter 2026 Earnings Results - CNO FINANCIAL GROUP INC

Financial Performance:

• Operating earnings per diluted share rose 47% YoY to $1.90, with year-to-date growth of 43% (45% excluding significant items).
• Total insurance product margin increased 7% YoY, driven by sales momentum and favorable trends, though partially offset by higher morbidity in Medicare Supplement and traditional life advertising expenses.
• Net investment income grew 13% YoY (12th consecutive quarter of growth); new money yield was 6.24%, up 9 bps YoY, with the top 15 consecutive quarters exceeding 6%.
• Operating return on equity (ROE) was 15.4% for the trailing 12 months (14.1% excluding significant items), benefiting from ~50 bps of unallocated net investment income outperformance.
• Expense ratio improved to 18.5% on a trailing 12-month basis (down 50 bps YoY), with full-year guidance raised to 18.6–18.8%.
• Book value per diluted share (excluding AOCI) increased 8% to $41.29.
• Capital return: $77 million returned to shareholders in the quarter, including $60 million in share repurchases, contributing to a 4% reduction in weighted average diluted shares outstanding.

Guidance and Future Outlook:

• Raised full-year 2026 operating earnings per share guidance to $5.05–$5.15 (9% midpoint increase), reflecting an operating effective tax rate of ~20.5% and fee income of ~$25 million.
• Full-year 2026 free cash flow guidance set at $220–$240 million, down from prior expectations due to higher capital consumption in the FHLB program and technology modernization spend ($70M total expected for the year).
• 2026 operating ROE is on track to exceed the prior 12% target set for year-end 2027; long-term targets to be revised in February 2027.
• Long-term goal is to achieve consistent top-quartile ROE performance among peers.
• Technology modernization (TechMod) cash spend is expected to be ~$45 million year-to-date and ~$70 million for the full year, with comparable spend expected in 2027.
• Expected to settle into a "run-rate cadence" for Bermuda operations in 2028 following 2027 optimization efforts.

Business Segments and Product Lines:

• Consumer Division: 16th consecutive quarter of sales growth; producing agent count up 4%. Medicare Supplement NAP surged 41% (QoQ) and >60% (12 months) due to a secular shift from Medicare Advantage; total Medicare policies up 20%. Direct-to-consumer NAP up 29% (excluding third-party pilot).
• Asset Accumulation: Fixed Indexed Annuity (FIA) premiums up 9% to $514 million; account values up 7%. Brokerage and advisory client assets hit a record $20 billion (up 15%); total accounts up 13%.
• Worksite Division: 18th consecutive quarter of sales growth; producing agent count up 6% to a record level. Life and health NAP up 18%, with life sales up 59% and new client NAP up 168%.
• Reinsurance: Completed third reinsurance treaty transferring $270 million of Colonial Penn U.S. statutory graded benefit life reserves to Bermuda affiliate (C&O Bermuda Re) effective October 1, enhancing liability diversification.

Market and Competitive Landscape:

• Medicare Advantage market disruption (3 million policies shifting due to carrier exits/benefit changes) is driving demand for Medicare Supplement, a key C&O differentiator.
• Competitive moat centered on the "last mile" captive agent distribution model for the middle market, difficult for competitors to replicate.
• Macroeconomic headwinds (inflation, interest rates) are not materially impacting demand for essential retirement and protection products among the middle-income demographic.
• Investment portfolio remains high-quality; increased allocation to private credit/ABF ($2B total private credit, ~$1B in ABF) focused on structured, investment-grade consumer credit to match ALM needs.

Risks and Challenges:

• Morbidity Trends: Higher claims experience in Medicare Supplement partially offset by block growth and rate increases.
• Expense Variability: D2C channel includes selective experimentation with third-party partners, creating potential quarterly variability in marketing spend.
• Regulatory/Actuarial: Statutory earnings impacts from GAAP assumption reviews are minimal as statutory reserves remain locked at issue; potential reversion to the mean in favorable experience trends.
• Investment Yield: Exceptional investment income outperformance (~$12M above long-term yield) is not expected to sustain; reliance on high-quality fixed income and alternatives for future yields.

Management Commentary and Tone:

• Tone was highly confident, emphasizing "consistent, repeatable results" and "durable competitive moat."
• Management highlighted the strength of the diversified business model and the resilience of the middle-income consumer segment against economic pressures.
• Expressed strong conviction in the long-term ROE improvement trajectory and the strategic value of the Bermuda reinsurance operations.
• Acknowledged that the favorable Q3 expense run is sustainable with potential for further improvement via operating leverage.

Analyst Questions and Answers:

• Free Cash Flow/Capital: Confirmed that the $270M Bermuda reinsurance transaction solved for excess capital held in Bermuda but also involved capital consumption for growth (FHLB) and tech; no specific dividends extracted from Bermuda yet.
• Bermuda Strategy: Decision to stop seeding additional in-force life blocks was strategic/optimal for liability diversification, not regulator-driven; focus now shifts to asset/capital optimization.
• Expense Ratio: Current favorable expense ratio is viewed as sustainable; improvements expected to continue as the business scales.
• ROE Outlook: ~50 bps of Q3 ROE was driven by unallocated NII outperformance; long-term trend remains upward despite potential mean reversion in specific experience factors.
• Medicare Dynamics: Confirmed that market dislocation in Medicare Advantage creates incremental opportunities for agents to advise clients on Supplements, aligning with C&O's relationship-based model.
• Assumption Review: GAAP reserve releases benefited FIA and annuities (lower surrender/utilization assumptions) and Medicare Supplement (run-rate adjustment); minimal direct statutory impact.

Other Key Points:

• 17th consecutive quarter of sales growth and 15th consecutive quarter of producing agent count growth across the enterprise.
• Non-televised marketing channels (web, digital, third-party) generated 71% of D2C life sales.
• New business strain in Medicare Supplement and FIA is offset by the "new money" yield environment and investment outperformance.
• The third Bermuda treaty involved 600,000+ policies, representing a substantial block despite being a subset of the overall life business.